Wu Chun

Managing Partner, Greater China, Boston Consulting Group

Dr. Chun Wu is the Managing Partner of BCG Greater China, overseeing BCG’s business across industry and functional practices in this region.

Under her leadership, BCG established Greater China Leadership Institute in 2022, providing strategic innovation and leadership coaching for companies in China. It gained recognition and popularity from C-suite leaders. Meanwhile, BCG has organized hundreds of high-level exchanges among global companies and industry associations, which pay close attention to the development of Chinese market, to enhance the cooperation between Chinese and International companies.

With over two decades of healthcare industry expertise, Dr. Wu previously headed BCG’s Healthcare practice in Greater China before assuming leadership of the firm’s regional operations. Her extensive consulting experience spans both domestic enterprises and multinational corporations, addressing critical areas and topics including healthcare industry policy, strategic business development, new product R&D and technology platform upgrades, operational excellence, digital transformation, and organizational change. Additionally, she possesses profound insights into macroeconomic trends, strategic innovation, organizational leadership, sustainability, and AI.

Dr. Wu is also a frequently invited speaker at premier business forums, including the China Development Forum, Boao Forum for Asia, World Economic Forum Annual Meeting of the New Champions, Yangtze River Delta Integration Development Forum, International BioPharma Industry Week Shanghai, and China Pharmaceutical Entrepreneurs Scientists Investors Conference. She has authored numerous influential publications, such as China’s Path to a Sustainable Future released during the China Development Forum, The Guide for Sustainable Development of Chinese Corporates (2022) in collaboration with the APEC China Business Council, Why Two Hearts Are Better Than One: How to Beat Your Rivals in a Bifurcated World, China Economic Review and Outlook, Beyond Efficiency: China’s Next Leap in Biopharma Innovation, China Synthetic Biology Industry Report 2024, Chinese Pharmaceutical Companies Going Global, China Consumer Healthcare Market Outlook, China’s Medical Device Innovation series, China Pharmaceutical Innovation series, and China Vaccine Industry Transformation series.

In recognition of her exceptional leadership and industry influence, Dr. Wu has been recognized as one of Fortune China’s Most Powerful Women in Business for two consecutive years (2023-2024) and was named to Forbes China’s Top Businesswomen list in 2026. Dr. Wu holds a B.S. degree in biochemistry from Peking University and a Ph.D. degree in Genetics from Yale University.

关于我们

加入我们

  • 登录
  • 成为我们的合作伙伴
  • 成为我们的会员
  • 订阅我们的新闻稿
  • 联系我们

快捷链接

语言版本

隐私政策和服务条款

站点地图

© 2026 世界经济论坛